News | September 09, 2009

ASCO Receives CEO Cancer Gold Standard Accreditation

ASCO CEO Allen S. Lichter, M.D.

September 9, 2009 - The American Society of Clinical Oncology (ASCO) has received CEO Cancer Gold Standard accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

The CEO Cancer Gold Standard calls for companies to evaluate their health benefits and corporate culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use; encouraging physical activity; promoting healthy diet, and nutrition; detecting cancer at its earliest stages; and providing access to quality care, including participation in clinical trials.

“We are very proud to gain this designation. It demonstrates an unwavering commitment to the health and well-being of our employees,” said ASCO CEO Allen S. Lichter, M.D. “As additional organizations become certified, we can make great strides in reducing cancer incidence and improving cancer treatment.”

William C. Weldon, chairman and chief executive officer of Johnson & Johnson chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard, in collaboration with the National Cancer Institute, many of its designated cancer centers, the CDC, and leading health non-profit organizations and professionals.

“As the world’s leading professional organization representing physicians who care for people with cancer, it is fitting that our Gold Standard certification demonstrates that ASCO also cares for its employees and their family members and supports efforts to reduce their cancer risk,” said William C. Weldon, chairperson and chief executive officer of Johnson & Johnson, who chairs the Roundtable.

The most recent President's Cancer Panel report, “Maximizing our Nation’s Investment in Cancer: Three Crucial Actions for America’s Health”, identified the CEO Cancer Gold Standard as an initiative that emphasizes cancer screening, tobacco control, cancer education, lifestyle modification, and access to cancer treatment when needed.

Other organizations joining ASCO in championing this workplace-based effort to eliminate cancer as a public health threat include: American Cancer Society, the American Legacy Foundation, C-Change, Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals, Fox Chase Cancer Center, GHI (an EmblemHealth company), Hogan & Hartson, Independence Blue Cross & Blue Shield, Jenner & Block, The Lance Armstrong Foundation, M. D. Anderson Cancer Center, Millennium: The Takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute, Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Quintiles Transnational, sanofi-aventis, SAS Institute, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, and Vanderbilt-Ingram Cancer Center.

For more information: www.asco.org and www.cancer.net

Related Content

Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...